Please assess the completion status of the following clinical trial:

Trial Title: Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has given written informed consent~* Subject has a diagnosis of moderate to severe chronic plaque psoriasis involving \>=10% with a Psoriasis Area and Severity Index (PASI) score \>=10 at Baseline~* Subject has CD4+ T lymphocyte (CD4) count at or above the lower limit of normal~* Male and female subjects must use an adequate means of contraception from screening to end of study.~Exclusion Criteria:~* Subject who received alefacept in the past~* Subject who has shown no improvement following an adequate course of nbUVB in the past~* Subject who has been treated in the past with either therapy or cyclosporine~* Subject with any active cancer, including skin cancer at Baseline~* Subject with erythrodermic, pustular or predominantly guttate psoriasis~* Subject who has used treatment for psoriasis prior to Baseline as follows:~  * Topical treatment within 14 days~ * Oral treatment within 28 days~ * Broad band UVB (bbUVB) or nbUVB treatment within 56 days~ * Biological treatment within 84 days~* Serious local infection or serious systemic infection within the 3 months prior to the first dose of study drug~* Subject with a history of drug or alcohol abuse within the past 2 years~* Subject that is known to be infected with the AIDS virus~* Subject with any other skin disease or other disease that might interfere with psoriasis status assessments~* Female subject who is nursing, pregnant or planning to become pregnant while in this study~* Subject who is currently enrolled in any other investigational drug or device study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alefacept alone (Type: ACTIVE_COMPARATOR): 15 mg alefacept intramuscularly (IM) once weekly for 12 weeks
- Alefacept + nbUVB (Type: EXPERIMENTAL): 15 mg alefacept intramuscularly once weekly and narrow band Ultraviolet B (nbUVB) phototherapy 3 times per week for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).